Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + CHEP in PTCL
NCT04061772Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in peripheral T-cell lymphoma (PTCL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Status: unknown.
02
Drugs
bortezomib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04061772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061772.